Immune checkpoint inhibitors (ICPIs) have transformed the landscape of oncology, but are
associated with a variety of autoimmune adverse events, including AKI. ICPI-associated AKI
(ICPI-AKI) is emerging as an increasingly frequent cause of AKI in patients with cancer, and
poses unique diagnostic and management challenges to clinicians who care for these
patients. In this review, we describe the incidence and risk factors for ICPI-AKI, including
proton pump inhibitor use, CKD, and combination immunotherapy. We discuss the …